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To the Editor: Canaud et al.1 reported a significant 35%
lower mortality risk with high-efficiency hemodiafiltration
(HDF) compared to low-flux hemodialysis. Patients on HDF
were slightly older, significantly heavier, and longer on renal
replacement therapy (higher co-morbidity). Thus, they were
possibly selected for HDF because of their higher risk profile.
We evaluated HDF data prospectively collected in EuCliD2
from 56 clinics in Czech Republic, Hungary, Italy, and UK, all
belonging to an International dialysis provider network. To
reduce bias related to different dialysis doses, only patients on
three times a week schedule achieving an eKt/VX1.20 were
considered. Out of 2564 prevalent patients, 394 were treated
with HDF and 2170 with hemodialysis over 12 months.
Similarly, patients on HDF were heavier (67.6 versus 65.9 kg,
P¼ 0.03) and longer on renal replacement therapy (6.6174.94
versus 4.9775.05 years, Po0.001); however, they were
significantly younger (52.7716.3 versus 59.7716.1 years,
Po0.001). Furthermore, they were more likely to be diabetic
(20.3 versus 18.3%) or affected by neoplasm (8.4 versus 6.7%).
High-flux polysulfone was usually used. Data on replacement
volume is not currently available but, as on-line HDF was
standard, volumes are likely to be high (15–25 l).
HDF resulted in a significant 42.7% reduction in mortality
risk (odds ratio: 0.573; 95% confidence interval: 0.377–0.873).
After adjustment for age, gender, co-morbidities, and time on
renal replacement therapy, mortality risk reduction was 35.3%
(odds ratio: 0.647; 95% confidence interval: 0.419–0.991) and
remained significant. In conclusion, our data confirm the
results of Canaud et al.1 However, epidemiological evaluations
have limitations. The potential survival benefit of HDF must
be tested by controlled clinical trials.
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Jirka et al.1 submit a very interesting letter confirming the
results recently reported with the International Dialysis
Outcomes and Practice Patterns Study.2 They observed a
35.3% reduction rate in mortality risk in online hemodia-
filtration (HDF)-treated patients belonging to an interna-
tional dialysis care provider (Fresenius Medical Care, Bad
Homburg, Germany), after adjustment for age, co-morbid-
ities, and time on dialysis. These data were prospectively
collected over 12 months through the European Clinical
Database (Euclid) network in 56 clinics. This database
includes 2564 prevalent hemodialysis patients, out of them
394 were treated by online HDF. Online HDF was
comparable in terms of efficacy to the high-efficiency
group of Dialysis Outcomes and Practice Patterns Study
with a 15–25 l fluid exchanged per session and a Kt/V
superior to 1.2. Today, it is not still well understood why
these convective therapies are superior to hemodialysis.
However, one can speculate that by enhancing both the
removal of middle molecules toxins (e.g., B2M) and the
biocompatibility of the dialysis system (ultrapurity of
dialysate, highly permeable synthetic membranes), these
methods improve substantially the efficiency and the
quality of the delivered treatment.3 As suggested by Jirka
et al.1 prospective controlled randomized studies hemo-
dialysis versus HDF are missing. This lack will be certainly
corrected with the three European ongoing studies on this
topic.4 This brief report is, nevertheless, a very strong
support to our findings showing that high-efficiency conve-
ctive therapies, such as online HDF, may offer an interesting
alternative to improve dialysis patient outcomes.
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